Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Leuk Lymphoma. 2020 Feb 8;61(6):1493–1499. doi: 10.1080/10428194.2020.1723014

Table 2.

Hypomethylating Agent Therapy and Response.

CMML (n=12) MDS (n=27) p
Hypomethylating Agent
Single-Agent Azacitidine 4 (33.3%) 13 (48.1%) 0.091
Single-Agent Decitabine 5 (41.7%) 3 (11.1%)
Azacitidine in Combination 2 (16.7%) 10 (37.0%)
Decitabine in Combination 1 (6.3%) 0
Other 0 1 (3.7%)
Response
Complete Remission (CR) 3 (25.0%) 11 (40.7%) 0.12
Marrow CR (mCR) 2 (16.7%) 0
Hematological Improvement (HI) 1 (6.3%) 5 (18.5%)
Overall Response Rate (ORR) 6 (50.0%) 16 (59.3%) 0.73